tiprankstipranks
Trending News
More News >

Kymera Therapeutics upgraded to Buy from Neutral at BofA

BofA analyst Tazeen Ahmad upgraded Kymera Therapeutics (KYMR) to Buy from Neutral with a price target of $51, up from $44.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue